Daiichi Sankyo Company, Limited DSNKY
17.68 USD -0.54 (-2.96%)
Nov 10, 2026, 3:58 PM EST
17.61 Day range 18.09
14.98 52-week range 24.77
- YTD
- -16.76%
- 1 year
- -17.58%
- Market cap
- 32.21B
- EPS (ttm)
- 0.97
- P/E ratio
- 18.23
- YTD return
- -16.76%
- 1-year return
- -17.58%
- Volume
- 2.93K
- Avg volume
- 147.14K
- Open
- 18.09
- Previous close
- 18.22
- Day's range
- 17.61 – 18.09
- 52-week range
- 14.98 – 24.77
- Earnings date
- Oct 30, 2026
5D +0.04 (+0.22%)
Next earnings
Oct 30, 2026
Expected Oct 30, 2026. Consensus EPS estimate 0.2362.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 30, 2026 | Sep 30, 2026 | 0.2362 | — | — | — |
| Jul 31, 2026 | Jun 30, 2026 | 0.2543 | 0.24 | -0.01 | -5.62% |
| May 11, 2026 | Mar 31, 2026 | 0.3317 | 0.1465 | -0.19 | -55.83% |
| Jan 29, 2026 | Dec 31, 2025 | 0.2504 | 0.3033 | +0.05 | +21.13% |
| Oct 31, 2025 | Sep 30, 2025 | 0.2986 | 0.1592 | -0.14 | -46.68% |
| Jul 31, 2025 | Jun 30, 2025 | 0.2337 | 0.3059 | +0.07 | +30.89% |
News
Daiichi Sankyo Company, Limited (DSNKY) Q2 2026 Earnings Call Transcript 
Daiichi Sankyo Reports Second Quarter Fiscal Year 2026 Financial Results 
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union 
Daiichi Sankyo Gets $75M Milestone From AstraZeneca After EU Approves Enhertu For Adjuvant HER2 Positive Early Breast Cancer; DESTINY-Breast05 Showed 53% Lower Recurrence Or Death Risk Versus T-DM1 
Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO 
COLL vs. DSNKY: Which Stock Is the Better Value Option? 
Daiichi Sankyo Company, Limited (DSNKY) Q1 2026 Earnings Call Transcript 
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership 
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination 
Summit Therapeutics, AstraZeneca And Daiichi Sankyo Announce Clinical Trial Collaboration To Evaluate Ivonescimab With TROP2-Directed ADC Datroway Across Multiple Tumor Types, Starting With Phase III First-Line Triple-Negative Breast Cancer Study
Your note
Sign in to keep a note on DSNKY — it syncs with the Stock Master app.